Intravenous immunoglobulin G selectively inhibits IL-1α-induced neutrophilendothelial cell adhesion

Autoimmunity

Volumn 43, Issue 8, 2010, Pages 619-627

  MacMillan, Heather F ^a   Rowter, Derek ^a   Lee, Tim ^a   Issekutz, Andrew C ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

endothelium; inflammation; IVIG; Leukocyte; recruitment

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL INTERACTION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOSTIMULATION; LEUKOCYTE; MALE; NEUTROPHIL; NORMAL HUMAN; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

CELL ADHESION; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; INTERLEUKIN-1ALPHA; NEUTROPHILS;

EID: 78149420319     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916931003599062     Document Type: Article

References (40)

1. Cunningham-Rundles C, Hanson LA, Hitzig WH, Knapp W Lambert P-H, Nydegger UE, Prince AM, Rosen FS, Seligmann M, Soothill JF, Thompson RA, Torrigiani G, Wedgwood RJ. Appropriate uses of human immunoglobulin in clinical practice: Memorandum from an IUIS/WHO meeting. Bull World Health Organ 1982;60(1):43-47.
2. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;317(8232):1228- 1231.
3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous immunoglobulin: An update on the clinical use and mechanisms of action. J Clin Immunol 2007;27(3): 233-245.
4. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP, Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology JAllergy Clin Immunol 2006;117(4 Suppl.):S525-S553.
5. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: The Massachusetts General Hospital data and a review of the literature. Transfusion 2006;46(5):741-753.
6. Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin\Reasons and possible sol-utions. Nat Clin Pract Neurol 2007;3(3):120-121.
7. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007;119(5): 1055-1062, quiz 1063-1064.
8. O'Donnell R, Breen D, Wilson S, Djukanovic R. Inflammatory cells in the airways in COPD. Thorax 2006;61(5):448-454.
9. Poubelle PE, Chakravarti A, Fernandes MJ, Doiron K, Marceau AA. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res Ther 2007;9(2):R25.
10. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: Present and future therapeutic targets. Nat Immunol 2005;6(12):1182-1190.
11. Smith CW. 3. Adhesion molecules and receptors. J Allergy Clin Immunol 2008;121(2 Suppl.):S375-S379, quiz S414.
12. Frenette PS, Wagner DD. Adhesion molecules\Part 1. N Engl J Med 1996;334(23):1526-1529.
13. Frenette PS, Wagner DD. Adhesion molecules\Part II: Blood vessels and blood cells. N Engl J Med 1996;335(1):43-45.
14. Luster AD. Chemokines\Chemotactic cytokines that med-iate inflammation. N Engl J Med 1998;338(7):436-445.
15. Wadhwa M, Meager A, Dilger P, Bird C, Dolman C, Das RG, Thorpe R. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. Immunology 2000;99(1):113-123.
16. Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. Immunol Today 1998;19(5): 209-211.
17. Vassilev TL, Kazatchkine MD, Van Huyen JP, Mekrache M, Bonnin E, Mani JC, Lecroubier C, Korinth D, Baruch D, Schriever F, Kaveri SV. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999;93(11):3624-3631.
18. Ichiyama T, Ueno Y, Isumi H, Niimi A, Matsubara T, Furukawa S. An immunoglobulin agent (IVIG) inhibits NF-kappaB activation in cultured endothelial cells ofcoronary arteries in vitro. Inflamm Res 2004;53(6):253-256.
19. Nakatani K, Takeshita S, Tsujimoto H, Sekine I. Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway. Clin Exp Immunol 2002;127(3): 445-454.
20. Xu C, Poirier B, Van Huyen JP, Lucchiari N, Michel O, Chevalier J, Kaveri S. Modulation ofendothelial cell function by normal polyspecific human intravenous immunoglobulins: A possible mechanism of action in vascular diseases. Am J Pathol 1998;153(4):1257-1266.
21. + movements and nitric oxide production in endothelial cells. J Biol Chem 1996;271(43):26473-26476.
22. Issekutz AC, Rowter D, Springer TA. Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligands in neutrophil transendothelial migration. J Leukoc Biol 1999;65(1): 117-126.
23. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52(11):2745-2756.
24. Morzycki W, Sadowska J, Issekutz AC Interleukin-1 and tumour necrosis factor alpha induced polymorphonuclear leukocyte-endothelial cell adhesion and transendothelial migration in vitro: The effect ofapical versus basal monolayer stimulation. Immunol Lett 1990;25(4):331-340.
25. Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 2003;48(12):3497-3502.
26. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev 1997;8(4):253-265.
27. Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P. Decoy receptors: A strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001;22(6):328-336.
28. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002;13(4-5):323-340.
29. Pan L, Kreisle RA, Shi Y. Expression ofendothelial cell IgG Fc receptors and markers on various cultures. Chin Med J (Engl) 1999;112(2):157-161.
30. Groger M, Fischer GF, Wolff K, Petzelbauer P. Immune complexes from vasculitis patients bind to endothelial Fc receptors independent of the allelic polymorphism of Fcgamma RIIa. J Invest Dermatol 1999;113(1):56-60.
31. Bendtzen K, Hansen MB, Ross C, Svenson M. Detection of autoantibodies to cytokines. Mol Biotechnol 2000;14(3): 251-261.
32. Graudal NA, Svenson M, Tarp U, Garred P, Jurik AG, Bendtzen K. Autoantibodies against interleukin 1alpha in rheumatoid arthritis: Association with long term radiographic outcome. Ann Rheum Dis 2002;61(7):598-602.
33. Gill V, Doig C, Knight D, Love E, Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005;112(13):2031-2039.
34. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 2006; 83(2):447S-455S.
35. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharma-col 2004;4(4):378-385.
36. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005;201(9):1355-1359.
37. Dinarello CA. Mutations in cryopyrin: Bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity. Arthritis Rheum 2007;56(9):2817-2822.
38. Bedini C, Nasorri F, Girolomoni G, Pita O, Cavani A. Antitumour necrosis factor-alpha chimeric antibody (inflix-imab) inhibits activation ofskin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol 2007;157(2):249-258.
39. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128(2):376-392.
40. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124(7):1774-1785.